The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BXCL701, first-in-class oral activator of systemic innate immunity pathway, combined with pembrolizumab (Keytruda) in men with metastatic castration-resistant prostate cancer (mCRPC).
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - AstraZeneca; Dendreon; Janssen
Research Funding - Abbvie (Inst); Amgen (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Xynomic Pharma
 
Dan Costin
No Relationships to Disclose
 
Jingsong Zhang
Honoraria - AstraZeneca/MedImmune; Merck; Sanofi
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Clovis oncology; Dendreon; Janssen Oncology; Seagen
Speakers' Bureau - AstraZeneca; Merck Sharp & Dohme; Sanofi
Research Funding - AstraZeneca/MedImmune (Inst)
 
Lawrence Ivan Karsh
Stock and Other Ownership Interests - Swan Valley Medical (I)
Honoraria - 3D Biopsy; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Dendreon; Foundation Medicine; Genomic Health; Janssen; Merck; Myriad Pharmaceuticals; Pfizer; Urogen pharma
Consulting or Advisory Role - 3D Biopsy; Abbvie; Astellas Pharma; Augmenix; Bayer; Dendreon; Ferring; Janssen; Pfizer; Precision Biopsy; Spectrum Pharmaceuticals
Speakers' Bureau - Amgen; Astellas Pharma; AstraZeneca; Bayer; Dendreon; Janssen; Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Augmenix (Inst); Bayer (Inst); CU Optics (Inst); Dendreon (Inst); Exact Sciences (Inst); Ferring (Inst); FKD Therapies (Inst); Genomic Health (Inst); Janssen (Inst); Merck (Inst); Myovant Sciences (Inst); Nucleix (Inst); Nymox (Inst); OPKO Biologics (Inst); Pfizer (Inst); Precision Biopsy (Inst); PrecisionMed (Inst); Roche (Inst); Siemens (Inst); Spectrum Pharmaceuticals (Inst); Urogen pharma (Inst); Veru (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; dendreon; Foundation Medicine; Janssen; Pfizer; Spectrum Pharmaceuticals
 
Diane I. Healey
Employment - BioXcel Therapeutics; Bristol-Myers Squibb
Stock and Other Ownership Interests - BioXcel Therapeutics; Bristol-Myers Squibb; Pfizer
 
Mark David Linch
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen Oncology
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen; MSD
 
Sreenivas Adurthi
Employment - BioXcel Therapeutics
Stock and Other Ownership Interests - BioXcel Therapeutics
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Ipsen; Janssen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi
 
Vince O'Neill
Employment - BioXcel Therapeutics
Stock and Other Ownership Interests - BioXcel Therapeutics
 
Paul Monk
Honoraria - Sanofi/Aventis
Consulting or Advisory Role - Dendreon
Speakers' Bureau - Janssen